Crystalline Forms of Orally Available Selective KIT and PDGFR Kinase Inhibitor
Summary
USPTO granted patent US12590095B2 to Sandoz AG on March 31, 2026, covering crystalline forms of avapritinib, a KIT and PDGFR kinase inhibitor. The patent (CPC C07D 487/04) protects polymorphs and hydrates of the compound for treating gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM). Inventors include Verena Adamer, Andrea Thaler, and Erwin Schreiner.
What changed
USPTO issued Patent No. US12590095B2 to Sandoz AG granting exclusive rights to crystalline avapritinib polymorphs, hydrates, and pharmaceutical compositions containing these forms. The patent covers methods of treatment for GIST and advanced systemic mastocytosis including aggressive systemic mastocytosis (ASM), SM-AHN, and mast cell leukemia (MCL). The patent application (No. 17625138) was filed on July 2, 2020, and contains 15 claims.
This patent grant does not impose compliance obligations on other pharmaceutical companies. Generic manufacturers seeking to produce avapritinib formulations must design around these crystal forms or await patent expiration. Freedom-to-operate analyses should consider this patent alongside other Orange Book-listed patents for avapritinib (e.g., US10975095B2) when evaluating market entry strategies.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor
Grant US12590095B2 Kind: B2 Mar 31, 2026
Assignee
SANDOZ AG
Inventors
Verena Adamer, Andrea Thaler, Erwin Schreiner
Abstract
The present invention relates to crystalline avapritinib, polymorphs and hydrates thereof as well as to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising crystalline avapritinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of patients with gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL).
CPC Classifications
C07D 487/04
Filing Date
2020-07-02
Application No.
17625138
Claims
15
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.